Combination of matrine and sorafenib decreases the aggressive phenotypes of hepatocellular carcinoma cells

21Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: The aim of this study was to determine the effects of matrine (a natural alkaloid) on sorafenib-induced cytotoxicty against hepatocellular carcinoma (HCC) cells, and to explore the molecular mechanisms involved. Methods: HepG2 and Hep3B cells were treated with matrine alone or in combination with sorafenib, and cell viability and apoptosis were assessed. The involvement of micro (mi)RNA-21 in the action of matrine was examined. Results: Matrine significantly augmented the antiproliferative activity of sorafenib in a dose-dependent manner. Matrine significantly increased apoptosis, coupled with enhanced cleavage of caspase-3 and poly (ADP-ribose) polymerase. miRNA-21-overexpressing HCC cells showed a marked decrease in matrine-induced growth suppression and the expression of phosphatase and tensin homolog (PTEN). The suppressive effect of combining matrine and sorafenib was significantly reduced by miRNA-21 overexpression or PTEN inhibition. Conclusion: Matrine in combination with sorafenib leads to increased cytotoxic effects against HCC cells, at least partially, via the suppression of miRNA-21 and the subsequent induction of PTEN.

Cite

CITATION STYLE

APA

Lin, Y., Lin, L., Jin, Y., Zhang, Y., Wang, D., Tan, Y., & Zheng, C. (2014). Combination of matrine and sorafenib decreases the aggressive phenotypes of hepatocellular carcinoma cells. Chemotherapy, 60(2), 112–118. https://doi.org/10.1159/000371736

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free